AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
HAMILTON, ON, June 17, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie) and TerraPower Isotopes, LLC (TPI) today announced a supply agreement under which TPI will provide its high-quality Actinium-225 (Ac-225) 1 isotope to support AtomVie's contract development and manufacturing (CDMO) activities in radiopharmaceuticals, providing an added value to its clients with Ac-225-based programs. The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases.
The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle.
"We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie.
"Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes.
This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies.
About AtomVie Global Radiopharma (AtomVie)
AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit https://www.atomvie.com/
About TerraPower Isotopes (TPI)
TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at https://www.terrapower.com/isotopes/
About TerraPower
TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs.
SOURCE AtomVie Global Radiopharma Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
INDRA SIGNS AGREEMENT WITH AXISCADES TO BOOST PRODUCTION OF CUTTING-EDGE SYSTEMS IN INDIA
Indra, a European-based global leader in defense, aerospace, and strategic systems, and AXISCADES a prominent technology solutions provider in defense, aerospace and strategic electronics, are proud to announce a strategic alliance. Indra is keen to acquire defense-related products and services from AXISCADES, which will be delivered through AXISCADES' comprehensive design, development, production, and supply chain center. Both companies are actively exploring joint product development for the Indian and global markets, potentially adapting existing Indra products or creating new ones specifically tailored to meet customer needs. PARIS, June 17, 2025 /CNW/ -- Paris Air Show -- Indra and the Indian technology company AXISCADES have signed an agreement to collaborate on the production of solutions for the aerospace and defense markets. Indra's CEO, José Vicente de los Mozos, and AXISCADES' Chairman, Dr. Sampath Ravinarayanan, signed the Memorandum of Understanding at the Aerospace Show taking place this week in Le Bourget, in the presence of Indra Chairman, Angel Escribano, and AXISCADES CEO & MD, Alfonso Martínez. The agreement aims to manufacture in India several Indra solutions, such as antennas for its Tactical Air Navigation Systems (TACAN), Distance Measuring Equipment (DME) that provides in-flight information to aircraft, and countermeasure systems, as part of a broader system designed by Indra to protect aircraft in flight from potential missile attacks using guided systems, such as the well-known MANPADS. The collaboration between the two companies strengthens Indra's position in the global aerospace systems market and its network of alliances with companies worldwide. At the same time, Indra contributes to enhancing the capabilities of Indian companies, in a country where it has maintained a strong presence for years as a provider of cutting-edge systems and technologies across various sectors. Notable achievements include systems delivered to the country's Armed Forces and projects for the modernization of civil air traffic management. Indra and AXISCADES are evaluating collaborations in MPA Airborne Solutions and exploring a dedicated partnership for DRDO CABS MRMR and MMMA programs. About AXISCADES AXISCADES is a leading technology and product company with over 25 years of experience in the aerospace, defense, and ESAI (Electronic Systems and Industrial Automation) sectors. It offers cutting-edge solutions ranging from conceptual design to manufacturing and certification, making it a preferred partner for OEMs (Original Equipment Manufacturers) and Tier 1 suppliers in these industries.
Cision Canada
5 hours ago
- Cision Canada
AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
HAMILTON, ON, June 17, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie) and TerraPower Isotopes, LLC (TPI) today announced a supply agreement under which TPI will provide its high-quality Actinium-225 (Ac-225) 1 isotope to support AtomVie's contract development and manufacturing (CDMO) activities in radiopharmaceuticals, providing an added value to its clients with Ac-225-based programs. The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases. The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle. "We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie. "Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes. This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies. About AtomVie Global Radiopharma (AtomVie) AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit About TerraPower Isotopes (TPI) TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at About TerraPower TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. SOURCE AtomVie Global Radiopharma Inc.
Cision Canada
5 hours ago
- Cision Canada
Torngat Metals secures $165 million in financing from Export Development Canada and Canada Infrastructure Bank Français
MONTREAL, June 17, 2025 /CNW/ - Torngat Metals Ltd., a Quebec-based rare earth development company, is pleased to announce the signing of a CA$110 million bridge loan facility agreement with Export Development Canada ("EDC"), and a loan commitment of up to CA$55 million from the Canada Infrastructure Bank ("CIB"), to support the next phase of its Strange Lake project. The Strange Lake project is unique due to its significant quantities of light and heavy rare earths, particularly dysprosium and terbium, which are essential to permanent magnets and low-carbon solutions. This CA$165 million of combined financing will enable Torngat Metals to carry out key pre-construction activities, including engineering and environmental studies, which are required to submit permit applications for project infrastructure in Quebec and Labrador. "I would like to thank EDC and the CIB for their confidence in our vision and for recognizing the strategic importance of Torngat Metals' rare earth project, which aims to establish a responsible rare earth supply chain in Canada, essential to the global energy transition," said Yves Leduc, Chief Executive Officer of Torngat Metals. "This financing comes at a critical juncture, as the Chinese monopoly of heavy rare earths drives the global permanent magnet shortage. Our partnership with these two renowned Canadian institutions will help us achieve key project milestones towards unlocking the largest supply by far of dysprosium and terbium outside China." "EDC is proud to be a financing partner to Torngat Metals as they advance the next phase of the Strange Lake mining project. It's a reflection of our commitment to supporting the development of Canadian rare earth minerals, a national strategic priority," says Alison Nankivell, EDC's President and CEO. "This early-stage bridge loan facility is a first for EDC and the financing will be used by Torngat Metals to undertake essential pre-construction work. We look forward to building on this partnership as part of our broader support to the Canadian mining and mining supply sector." "We are proud to partner with Torngat Metals to advance the Strange Lake project – our first in the critical minerals sector," says Ehren Cory, CEO, Canada Infrastructure Bank. "Collaboration with the private sector to catalyze investment in rare earth mineral deposits and advance nationally significant projects will strengthen Canada's position in the global export markets." Funds from both the EDC and CIB will be released in phases, aligned with specific project milestones that involve detailed engineering and environmental compliance. Additionally, Torngat Metals intends to launch a limited recourse project financing later in 2025, with the intention of completing the Project Financing before the end of next year. Rothschild & Co acted as financial advisor to Torngat Metals, with Sullivan & Cromwell LLP and Stikeman Elliott LLP acted as legal counsel with respect to bridge financing. These advisors continue to advise Torngat on the Project Financing. About EDC Export Development Canada (EDC) is a financial Crown corporation dedicated to helping Canadian businesses make an impact at home and abroad. EDC has the financial products and knowledge Canadian companies need to confidently enter new markets, reduce financial risk and grow their business as they go from local to global. Together, EDC and Canadian companies are building a more prosperous, stronger and sustainable economy for all Canadians. For more information and to learn how we can help your company, call us at 1-800-229-0575 or visit About the Canada Infrastructure Bank The Canada Infrastructure Bank (CIB) invests in revenue-generating infrastructure which benefits Canadians and attracts private capital. The CIB is a catalyst for private investment in projects that support economic growth. The CIB is working on investment opportunities, from coast to coast to coast, which reflect our priority sectors for investment – green infrastructure, clean power, public transit, trade and transportation and broadband infrastructure About Torngat Metals Ltd. Torngat Metals is a private company based in Canada working to develop the Strange Lake Rare Earth Project to responsibly supply rare earth elements required for high-tech and low-carbon solutions. With development activities in Quebec, Newfoundland, and Labrador, the company aims to be a globally recognized supplier of light rare earths and a global leader in solving the heavy rare earth supply crisis for dysprosium and terbium. Leveraging robust partnerships with Indigenous peoples and local communities, new approaches to minimizing environmental impacts, and cutting-edge engineering, Torngat Metals looks forward to playing a pivotal role in the global transition to clean energy. Learn more at
